Combination therapy with polymyxin B and netropsin against clinical isolates of multidrug-resistant Acinetobacter baumannii

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chung, Joon Hui ^a,b   Bhat, Abhayprasad ^a   Kim, Chang Jin ^a,b   Yong, Dongeun ^c   Ryu, Choong Min ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CONGOCIDINE; POLYMYXIN B;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL; ANIMAL MODEL; COMBINATION DRUG THERAPY; DRUG EFFECT; DRUG POTENTIATION; ESCHERICHIA COLI; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOTH; MULTIDRUG RESISTANCE; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SHIGELLA FLEXNERI;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, ANIMAL; MOTHS; NETROPSIN; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; SHIGELLA FLEXNERI;

EID: 84975468448     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28168     Document Type: Article

References (43)

1. Nikaido, H. Multidrug Resistance in Bacteria. Annu. Revi. Biochem. 78, 119-146 (2009).
2. Spellberg, B. The future of antibiotics. Crit. Care 18, 228-228 (2014).
3. Perez, F. et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Ch. 51, 3471-3484 (2007).
4. Olaitan, A. O., Morand, S. & Rolain, J.-M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front. Microbiol. 5, 643 (2014).
5. Worthington, R. J. & Melander, C. Combination approaches to combat multidrug-resistant bacteria. Trends. Biotechnol. 31, 177-184 (2013).
6. Bergogne-Berezin, E. & Towner, K. J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9, 148-165 (1996).
7. Hermsen, E. D., Sullivan, C. J. & Rotschafer, J. C. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis. Clin. North. Am. 17, 545-562 (2003).
8. Shaheen, M. et al. Paenibacillus polymyxa PKB1 Produces Variants of Polymyxin B-Type Antibiotics. Chem. Biol. 18, 1640-1648 (2011).
9. Kim, K.-s., Kim, T. & Pan, J.-G. In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria. J. Antibiot. 68, 395-398 (2015).
10. Worthington, R. J. & Melander, C. Overcoming resistance to beta-lactam antibiotics. J. Org. Chem. 78, 4207-4213 (2013).
11. Huttner, B. et al. Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs medical centers, 2005-2010. PloS one 7, e36649 (2012).
12. Falagas, M. E. & Kasiakou, S. K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10, R27-R27 (2006).
13. Kopka, M. L. et al. The molecular origin of DNA-drug specificity in netropsin and distamycin. P. Natl. Acad. Sci USA 82, 1376-1380 (1985).
14. Lipfert, J., Klijnhout, S. & Dekker, N. H. Torsional sensing of small-molecule binding using magnetic tweezers. Nucleic Acids Res. 38, 7122-7132 (2010).
15. Tabernero, L. et al. Molecular structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor groove binding drug netropsin. Biochemistry 32, 8403-8410 (1993).
16. DeLong, E. F. Archaea in coastal marine environments. P. Natl. Acad. Sci. USA 89, 5685-5689 (1992).
17. Finlay, A. C. et al. Netropsin, a New Antibiotic Produced by a Streptomyces. J. Am. Chem. Soc. 73, 341-343 (1951).
18. Hao, C. et al. Mining of the pyrrolamide antibiotics analogs in Streptomyces netropsis reveals the amidohydrolase-dependent "iterative strategy" underlying the pyrrole polymerization. PloS one 9, e99077 (2014).
19. Tsai, C. J., Loh, J. M. & Proft, T. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence 1-16 (2016).
20. Zavascki, A. P. et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemoth. 60, 1206-1215 (2007).
21. Barrios-Gonzalez, J., Fernandez, F. & Tomasini, A. Microbial secondary metabolites production and strain improvement. Indian J. Biotechnol. 2, 322-333 (2003).
22. Kwa, A. et al. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti. Infect. Ther. 5, 811-821 (2007).
23. Lown, J. W. et al. Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation. J. Med. Chem. 32, 2368-2375 (1989).
24. Hahn, F. E. Distamycin and Netropsin. In: Corcoran, J. W., Hahn, F. E., Snell, J. F. & Arora, K. L., eds. Mechanism of Action of Antimicrobial and Antitumor Agents Berlin Heidelberg: Springer Berlin Heidelberg, 79-100 (1975).
25. Snounou, G. & Malcom, A. D. Production of positively supercoiled DNA by netropsin. J. Mol. Biol. 167, 211-216 (1983).
26. Barrett, M. P., Gemmell, C. G. & Suckling, C. J. Minor groove binders as anti-infective agents. Pharmacol. Therapeut. 139, 12-23 (2013).
27. Hill, L., Veli, N. & Coote, P. J. Evaluation of Galleria mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection. Int. J. Antimicrob. Ag. 43, 254-261 (2013).
28. Sobieszczyk, M. E. et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 54, 566-569 (2004).
29. Schindler, P. R. G. & Teuber, M. Action of Polymyxin B on Bacterial Membranes: Morphological Changes in the Cytoplasm and in the Outer Membrane of Salmonella typhimurium and Escherichia coli B. Antimicrob. Agents Ch. 8, 95-104 (1975).
30. Hancock, R. E. W. The bacterial outer membrane as a drug barrier. Trends Microbiol. 5, 37-42 (1997).
31. Morita, Y., Tomida, J. & Kawamura, Y. Responses of Pseudomonas aeruginosa to antimicrobials. Front. Microbiol. 4, 422 (2013).
32. Hong, S. K. et al. Establishing Quality Control Ranges for Antimicrobial Susceptibility Testing of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus: A Cornerstone to Develop Reference Strains for Korean Clinical Microbiology Laboratories. Ann. Lab. Med. 35, 635-638 (2015).
33. Kim, Y. et al. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn. Micr. Infec. Dis. 79, 362-366 (2014).
34. Hayakawa, M. & Nonomura, H. Humic acid-vitamin agar, a new medium for the selective isolation of soil actinomycetes. J. Ferment. Technol. 65, 501-509 (1987).
35. Reasoner, D. J. & Geldreich, E. E. A new medium for the enumeration and subculture of bacteria from potable water. Appl. Environ. Microb 49, 1-7 (1985).
36. Elipoulos, G. M. & Moellering, R. C. Antimicrobial combinations. In: Lorian V., 4th edn, Antibiotics in Laboratory Medicine. USA: Williams & Wilkins, 330-396 (1996).
37. Tamaoka, J. & Komagata, K. Determination of DNA base composition by reversed-phase high-performance liquid chromatography. FEMS Microbiol. Lett. 25, 125-128 (1984).
38. Chun, J. et al. EzTaxon: a web-based tool for the identification of prokaryotes based on 16S ribosomal RNA gene sequences. Int. J. Syst. Evol. Micr. 57, 2259-2261 (2007).
39. Gales, A. C., Reis, A. O. & Jones, R. N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39, 183-190 (2001).
40. Lat, A. et al. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J. Clin Microbiol. 49, 1795-1798 (2011).
41. Oyedemi, S. et al. Compositions and comparisons of antimicrobial potencies of some essential oils and antibiotics against selected bacteria. Afr. J. Biotechnol. 7 (2008).
42. Dong, X. et al. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii. J. Antibiot. 67, 677-680 (2014).
43. Wand, M. et al. Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis. BMC Microbiol. 11, 11 (2011).